We are live on ! Find out more
REGN icon

Regeneron Pharmaceuticals
REGN

1,331 hedge funds and large institutions have $98.9B invested in Regeneron Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 125 funds opening new positions, 545 increasing their positions, 428 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 125 | Existing positions closed: 84

27% more repeat investments, than reductions

Existing positions increased: 545 | Existing positions reduced: 428

16% more funds holding in top 10

Funds holding in top 10: 25 → 29 (+4)

11% more capital invested

Capital invested by funds: $89.2B → $98.9B (+$9.73B)

2% more funds holding

Funds holding: 1,309 → 1,331 (+22)

0.59% more ownership

Funds ownership: 86.29% → 86.89% (+0.59%)

30% less call options, than puts

Call options by funds: $1.09B | Put options by funds: $1.55B

Holders
1,331
Holders Change
+22
Holders Change %
+1.68%
% of All Funds
19.22%
Holding in Top 10
29
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+16%
% of All Funds
0.42%
New
125
Increased
545
Reduced
428
Closed
84
Calls
$1.09B
Puts
$1.55B
Net Calls
-$465M
Net Calls Change
+$195M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$533M
2
Goldman Sachs
Goldman Sachs
New York
+$298M
3
Franklin Resources
Franklin Resources
California
+$222M
4
Capital Research Global Investors
Capital Research Global Investors
California
+$160M
5
UBS AM
UBS AM
Illinois
+$158M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$140M
2
Marshall Wace
Marshall Wace
United Kingdom
-$137M
3
BlackRock
BlackRock
New York
-$119M
4
Pictet Asset Management
Pictet Asset Management
Switzerland
-$107M
5
Caisse de Depot et Placement du Quebec (CDPQ)
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
-$86.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1051
Geller Advisors
New York
$264K – – –
TA
1052
TLS Advisors
Florida
$263K – – –
CAM
1053
Campion Asset Management
Virginia
$263K – – –
ECM
1054
Estabrook Capital Management
New York
$263K – – –
RB
1055
Rodgers Brothers
Pennsylvania
$263K – – –
TIA
1056
Tiemann Investment Advisors
California
$263K – – –
T
1057
Tidemark
California
$262K +$5.82K +6 +2%
LI
1058
LRI Investments
Florida
$261K +$238K +245 +6,125%
1CM
1059
1492 Capital Management
Wisconsin
$261K +$22.3K +23 +10%
OFG
1060
Oxford Financial Group
Indiana
$261K +$240K +248 New
RSWM
1061
Robertson Stephens Wealth Management
California
$260K +$239K +247 New
JIP
1062
Jaffetilchin Investment Partners
Florida
$258K -$1.94K -2 -0.8%
ACM
1063
Adalta Capital Management
New York
$258K – – –
AWM
1064
Accurate Wealth Management
Florida
$254K +$9.69K +10 +4%
GLA
1065
Good Life Advisors
Pennsylvania
$252K +$5.82K +6 +3%
HW
1066
Hamilton Wealth
California
$252K -$214K -221 -48%
QP
1067
Quilter Plc
United Kingdom
$250K +$231K +238 New
KLWA
1068
Kelly Lawrence W & Associates
California
$250K +$3.88K +4 +2%
KAS
1069
KPP Advisory Services
Kentucky
$247K -$3.88K -4 -2%
PS
1070
Planned Solutions
California
$246K – – –
AAM
1071
Aureus Asset Management
Massachusetts
$245K – – –
SWMP
1072
Signature Wealth Management Partners
New Jersey
$245K – – –
CH
1073
Cromwell Holdings
Wyoming
$245K +$226K +233 New
PSP
1074
Principal Street Partners
Tennessee
$244K – – –
CA
1075
Commerzbank Aktiengesellschaft
Germany
$243K +$224K +231 New
41 42
43
44 45

REGN Hedge Fund Activity: Q2 2024 in Review

1,331 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2024, worth a combined $98.9B — up 11% from $89.2B a quarter earlier.

Buyers outnumbered sellers: 125 funds opened new REGN positions and 84 closed out — a net gain of 41 holders — while 545 added to existing stakes and 428 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $533M. The largest seller was Fidelity Investments, cutting an estimated $140M.

  • 1,331 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2024, up from 1,309 in Q1 2024.
  • Funds reported $98.9B of Regeneron Pharmaceuticals stock for Q2 2024, up 11% quarter-over-quarter.
  • 125 funds opened new Regeneron Pharmaceuticals positions in Q2 2024 and 84 closed out, a net change of +41 holders.
  • The largest Regeneron Pharmaceuticals buyer in Q2 2024 was JP Morgan Chase, an estimated $533M added.
  • The largest Regeneron Pharmaceuticals seller in Q2 2024 was Fidelity Investments, an estimated $140M sold.

Based on aggregated 13F filings for Q2 2024.